CD33-Targeting siRNA Compositions for Neuroinflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics lack the ability to selectively diminish CD33 activity effectively for the treatment of neuroinflammatory diseases such as Alzheimer's disease.
Innovation Solution
The use of small interfering RNA (siRNA) molecules that target CD33 mRNA transcripts to silence CD33 gene expression, thereby reducing Siglec3 protein levels, is employed through direct delivery to target tissues using various injection methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutics are used to treat neuroinflammatory diseases, then treatment is provided, but they lack the ability to selectively diminish CD33 activity
Solution Approach 1:
The patent uses siRNA molecules as intermediaries to selectively target and silence CD33 gene expression. The siRNA acts as a mediator between the therapeutic goal (reducing CD33 activity) and the molecular target (CD33 mRNA), providing high selectivity through sequence-specific hybridization to the CD33 transcript while avoiding off-target effects on other genes.
2Reliability
If siRNA molecules are used to silence CD33, then selective silencing is achieved, but delivery to target tissue requires complex injection methods
Solution Approach 1:
The patent employs various delivery systems as intermediaries to transport siRNA molecules to target tissues. These may include liposomal carriers, nanoparticles, or conjugated molecules that facilitate cellular uptake and protect the siRNA from degradation, thereby enabling selective CD33 silencing without requiring direct intracerebral injection in all cases.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides selective silencing of CD33, preventing disease onset or progression by modulating neuroinflammation, thus offering a potential treatment for neuroinflammatory diseases like Alzheimer's disease.
Implementation Method 1
The antisense strand has complementarity sufficient to hybridize to a region within a CD33 mRNA transcript
Implementation Method 2
small interfering RNA (siRNA)-mediated silencing of CD33 transcripts
Data Source
AI summary
The present disclosure provides single- or double-stranded interfering RNA molecules (e.g., siRNA) that target a SiglecS (CD33) gene. The interfering RNA molecules may contain specific patterns of nucleoside modifications and internucleoside linkage modifications, as pharmaceutical compositions including the same. The siRNA molecules may be branched siRNA molecules, such as di-branched, tri-branched, or tetra-branched siRNA molecules. The disclosed siRNA molecules may further feature a 5′ phosphorus stabilizing moiety and/or a hydrophobic moiety. Additionally, the disclosure provides methods for delivering the siRNA molecule of the disclosure to the central nervous system of a subject, such as a subject identified as having a neuroinflammatory disease (e.g., Alzheimer's disease).